XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.57%20.67B | -5.71%5.07B | 1.11%5.12B | 0.41%5.1B | 6.91%5.37B | 7.17%20.55B | 7.80%5.38B | 5.52%5.07B | 9.57%5.08B | 5.82%5.02B |
Operating revenue | 0.57%20.67B | -5.71%5.07B | 1.11%5.12B | 0.41%5.1B | 6.91%5.37B | 7.17%20.55B | 7.80%5.38B | 5.52%5.07B | 9.57%5.08B | 5.82%5.02B |
Cost of revenue | 1.59%3.65B | -0.11%930M | 0.46%881M | 1.91%908M | 4.15%928M | 9.69%3.59B | 8.26%931M | 7.34%877M | 9.86%891M | 13.50%891M |
Gross profit | 0.35%17.02B | -6.88%4.14B | 1.24%4.24B | 0.10%4.2B | 7.51%4.44B | 6.65%16.96B | 7.70%4.45B | 5.15%4.19B | 9.51%4.19B | 4.29%4.13B |
Operating expense | -2.85%14.1B | -9.66%3.37B | -2.11%3.53B | -2.66%3.52B | 3.31%3.68B | 7.61%14.52B | 6.10%3.73B | 6.08%3.61B | 11.09%3.62B | 7.35%3.57B |
Selling and administrative expenses | -3.77%8.8B | -9.55%2.09B | -3.06%2.22B | -5.12%2.17B | 2.79%2.32B | 3.41%9.15B | 0.39%2.32B | 2.60%2.29B | 7.48%2.29B | 3.48%2.26B |
-General and administrative expense | -3.77%8.8B | -9.55%2.09B | -3.06%2.22B | -5.12%2.17B | 2.79%2.32B | 3.41%9.15B | 0.39%2.32B | 2.60%2.29B | 7.48%2.29B | 3.48%2.26B |
Depreciation amortization depletion | -5.98%818M | -10.65%193M | -6.70%209M | -2.35%208M | -4.15%208M | 3.45%870M | 1.41%216M | 7.18%224M | -1.39%213M | 6.90%217M |
-Depreciation and amortization | -5.98%818M | -10.65%193M | -6.70%209M | -2.35%208M | -4.15%208M | 3.45%870M | 1.41%216M | 7.18%224M | -1.39%213M | 6.90%217M |
Other operating expenses | -0.38%4.48B | -9.72%1.08B | 0.82%1.11B | 2.33%1.14B | 5.87%1.15B | 18.27%4.5B | 20.36%1.19B | 13.90%1.1B | 22.48%1.12B | 16.45%1.09B |
Operating profit | 19.40%2.92B | 7.47%777M | 22.11%707M | 17.36%676M | 33.98%757M | 1.29%2.44B | 16.80%723M | -0.34%579M | 0.52%576M | -11.58%565M |
Net non-operating interest income expense | 8.32%-826M | 10.57%-203M | 11.01%-202M | 10.18%-203M | 1.36%-218M | -1.24%-901M | -3.65%-227M | -2.25%-227M | -1.80%-226M | 2.64%-221M |
Non-operating interest expense | -8.32%826M | -10.57%203M | -11.01%202M | -10.18%203M | -1.36%218M | 1.24%901M | 3.65%227M | 2.25%227M | 1.80%226M | -2.64%221M |
Other net income (expense) | 4,109.33%3.16B | 252.17%81M | 6,057.14%417M | 395.65%114M | 6,969.44%2.55B | 142.13%75M | 129.11%23M | -133.33%-7M | 126.74%23M | 205.88%36M |
Earnings from equity interest | 14.04%260M | 6.85%78M | 21.57%62M | 12.96%61M | 18.00%59M | 5.56%228M | 12.31%73M | 0.00%51M | 0.00%54M | 8.70%50M |
Special income (charges) | 1,711.05%2.77B | 44.26%-34M | 616.13%320M | 164.86%24M | 20,608.33%2.46B | 57.43%-172M | 58.78%-61M | -72.22%-62M | 73.57%-37M | 85.00%-12M |
-Less:Restructuring and merger&acquisition | ---- | ---- | -42.42%19M | 86.67%28M | 30.00%26M | -28.79%94M | -40.91%26M | 57.14%33M | -71.15%15M | 33.33%20M |
-Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | -54.26%43M | ---- | ---- | ---- | ---- |
-Less:Other special charges | -25.86%43M | -10.53%17M | -35.71%9M | -76.19%5M | 200.00%12M | -67.60%58M | -5.00%19M | 16.67%14M | -75.00%21M | -93.65%4M |
-Write off | --102M | --27M | --0 | 0.00%1M | 0.00%1M | ---- | ---- | 366.67%14M | -80.00%1M | 0.00%1M |
-Gain on sale of business | 12,578.26%2.92B | -9.09%10M | 34,900.00%348M | --58M | 19,130.77%2.5B | 2,200.00%23M | 1,000.00%11M | ---1M | --0 | 1,400.00%13M |
Other non- operating income (expenses) | 563.16%126M | 236.36%37M | 775.00%35M | 383.33%29M | 1,350.00%25M | 90.00%19M | 175.00%11M | -33.33%4M | --6M | ---2M |
Income before tax | 224.55%5.25B | 26.20%655M | 167.25%922M | 57.37%587M | 711.58%3.08B | 20.31%1.62B | 61.68%519M | -9.21%345M | 40.75%373M | 0.53%380M |
Income tax | 286.93%1.18B | 31.75%83M | 205.06%241M | 37.50%110M | 792.86%750M | -11.05%306M | 34.04%63M | -29.46%79M | -6.98%80M | -15.15%84M |
Net income | 209.99%4.06B | 25.44%572M | 156.02%681M | 62.80%477M | 688.51%2.33B | 30.97%1.31B | 66.42%456M | -0.75%266M | 63.69%293M | 5.71%296M |
Net income continuous Operations | 209.99%4.06B | 25.44%572M | 156.02%681M | 62.80%477M | 688.51%2.33B | 31.10%1.31B | 66.42%456M | -0.75%266M | 63.69%293M | 6.09%296M |
Net income discontinuous operations | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Minority interest income | 23.43%864M | 19.81%254M | 26.67%209M | 28.24%218M | 19.61%183M | 18.64%700M | 23.26%212M | 20.44%165M | 20.57%170M | 9.29%153M |
Net income attributable to the parent company | 423.73%3.2B | 30.33%318M | 367.33%472M | 110.57%259M | 1,404.20%2.15B | 48.66%611M | 139.22%244M | -22.90%101M | 223.68%123M | 2.14%143M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 423.73%3.2B | 30.33%318M | 367.33%472M | 110.57%259M | 1,404.20%2.15B | 48.66%611M | 139.22%244M | -22.90%101M | 223.68%123M | 2.14%143M |
Basic earnings per share | 449.42%33.02 | 38.02%3.34 | 397.98%4.93 | 119.83%2.66 | 1,442.86%21.6 | 56.51%6.01 | 146.94%2.42 | -18.18%0.99 | 245.71%1.21 | 7.69%1.4 |
Diluted earnings per share | 472.68%32.7 | 44.35%3.32 | 420.21%4.89 | 129.57%2.64 | 1,519.70%21.38 | 50.66%5.71 | 150.00%2.3 | -18.97%0.94 | 228.57%1.15 | 3.13%1.32 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |